Related Experiment Video

Updated: Feb 25, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

Cholesterol Management in the Era of PCSK9 Inhibitors

Anna Svatikova1, Stephen L Kopecky2

  • 1Department of Cardiovascular Medicine, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA.

Current Cardiology Reports
|August 6, 2017
PubMed

Insights

Aggressive low-density lipoprotein (LDL) cholesterol reduction is vital for heart disease prevention. Novel PCSK9 inhibitors effectively lower LDL, but high costs hinder widespread adoption and require further cost-effectiveness analysis.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Cholesterol management is crucial for preventing heart disease.
  • Statins are first-line therapy for hyperlipidemia, but often insufficient.
  • Achieving target low-density lipoprotein (LDL) levels remains a challenge for many patients.

Purpose of the Study:

  • To discuss current cholesterol management strategies.
  • To evaluate the role of novel therapies like PCSK9 inhibitors.
  • To assess the benefits and challenges associated with PCSK9 inhibitors.

Main Methods:

  • Review of current literature on cholesterol management.
  • Analysis of data on PCSK9 inhibitors' efficacy in lowering LDL.
  • Examination of cost-effectiveness studies and healthcare system impact.

Main Results:

  • PCSK9 inhibitors significantly reduce LDL cholesterol levels.
  • Concerns exist regarding the high cost and added value of PCSK9 inhibitors.
  • Current cost-effectiveness analyses are inconclusive, suggesting a need for cost reduction.

Conclusions:

  • PCSK9 inhibitors offer a promising approach for aggressive LDL reduction.
  • Further outcome data and comprehensive cost-effectiveness analyses are essential.
  • Addressing cost barriers is critical for patient, physician, and payer acceptance of PCSK9 inhibitors.
Abstract

Keywords:
Cardiovascular diseaseCholesterolPCSK9 inhibitorsPreventionStatins

More Related Videos

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK908:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.7K
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.6K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
482
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
755
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.7K
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
347
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49